Chronic kidney disease (CKD) is a major health problem worldwide and, in Spain, it is present in 15.1% of individuals. CKD is frequently associated with some comorbidities and patients need to be prescribed multiple medications. Polypharmacy increases the risk of adverse drug reactions (ADRs). There are no published studies evaluating the prevalence of potential drug–drug interactions (pDDIs) among CKD patients in any European country. This study was aimed to determine the prevalence, pattern, and factors associated with pDDIs among CKD patients using a drug interactions program. An observational cross-sectional study was carried out at Plasencia Hospital, located in Spain. Data were collected among patients with CKD diagnoses and pDDIs were assessed by the Lexicomp^® Drug Interactions platform. Data were obtained from 112 CKD patients. A total number of 957 prescribed medications were acknowledged, and 928 pDDIs were identified in 91% of patients. Age and concomitant drugs were significantly associated with the number of pDDIs (p < 0.05). According to the results, the use of programs for the determination of pDDIs (such as Lexicomp^®) is recommended in the clinical practice of CKD patients in order to avoid serious adverse effects, as is paying attention to contraindicated drug combinations.

中文翻译：

---

西班牙一家医院的慢性肾脏病患者中潜在的药物相互作用的患病率。

慢性肾脏病（CKD）是全球范围内的主要健康问题，在西班牙，慢性肾病（CKD）的患病率为15.1％。CKD经常与某些合并症相关，需要为患者开多种药。多元药房会增加药物不良反应（ADR）的风险。在任何欧洲国家，尚无发表的研究评估CKD患者之间潜在的药物相互作用（pDDI）的发生率。本研究旨在通过药物相互作用程序确定CKD患者中pDDI的患病率，模式和相关因素。观察性横断面研究在西班牙的普拉森西亚医院进行。数据CKD患者的诊断和pDDIs中收集由Lexicomp进行了评估^®药物相互作用平台。数据来自112位CKD患者。总共承认957种处方药，在91％的患者中鉴定出928个pDDI。年龄和伴随药物与pDDI数量显着相关（p <0.05）。根据研究结果，对pDDIs测定（如Lexicomp使用的程序^® CKD患者的临床实践建议，以避免严重的不利影响），因为被关注禁忌药物组合。